UK markets closed

Denali Therapeutics Inc. (DNLI)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
23.58-0.82 (-3.36%)
As of 11:45AM EDT. Market open.

Denali Therapeutics Inc.

161 Oyster Point Boulevard
2nd Floor
South San Francisco, CA 94080
United States
650 866 8548
https://www.denalitherapeutics.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees380

Key executives

NameTitlePayExercisedYear born
Dr. Ryan J. Watts Ph.D.Co-Founder, Pres, CEO & Director1.13MN/A1976
Dr. Alexander O. Schuth M.D.Co-Founder, CFO, COO & Sec.755.81k444.83k1973
Dr. Marc Tessier-Lavigne Ph.D.Co-Founder, Chairman of Scientific Advisory Board & Independent Director58.14kN/A1960
Dr. Carole Ho M.D.Chief Medical Officer & Head of Devel.769.39kN/A1973
Mr. Steve Edward KrognesTreasurer & Director813.44kN/A1968
Mr. Tyler M. NielsenVP of Corp. Fin.N/AN/A1978
Dr. Dana AndersenChief Technical and Manufacturing OfficerN/AN/AN/A
Mr. Joe LewcockChief Scientific OfficerN/AN/AN/A
Dr. Laura HansenVP of Investor RelationsN/AN/AN/A
Mr. Chris WalshAssociate Gen. CounselN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Corporate governance

Denali Therapeutics Inc.’s ISS governance QualityScore as of 1 May 2022 is 7. The pillar scores are Audit: 2; Board: 7; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.